ID   TPC-1
AC   CVCL_6298
DR   BTO; BTO:0006508
DR   BCRJ; 0397
DR   ChEMBL-Cells; CHEMBL3308064
DR   ChEMBL-Targets; CHEMBL613836
DR   CLS; 305054
DR   Cosmic; 686571
DR   Cosmic; 686572
DR   Cosmic; 686728
DR   Cosmic; 849969
DR   Cosmic; 931238
DR   Cosmic; 1021385
DR   Cosmic; 1084277
DR   Cosmic; 1132593
DR   Cosmic; 1152124
DR   Cosmic; 1237448
DR   Cosmic; 1239954
DR   Cosmic; 1280041
DR   Cosmic; 2036695
DR   Cosmic; 2054096
DR   Cosmic; 2319845
DR   Cosmic; 2613255
DR   IARC_TP53; 25009
DR   Millipore; SCC147
DR   PubChem_Cell_line; CVCL_6298
DR   TOKU-E; 4065
DR   Wikidata; Q54972844
RX   PubMed=2334411;
RX   PubMed=2516841;
RX   PubMed=2823470;
RX   PubMed=7491517;
RX   PubMed=11439348;
RX   PubMed=14522906;
RX   PubMed=15980887;
RX   PubMed=16778181;
RX   PubMed=17725429;
RX   PubMed=17804723;
RX   PubMed=18713817;
RX   PubMed=19087340;
RX   PubMed=21868764;
RX   PubMed=22087789;
RX   PubMed=23162534;
RX   PubMed=23833040;
RX   PubMed=30737244;
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (PubMed=7491517; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Omics: Mitochondrial genome sequenced.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): Millipore=SCC147; PubMed=18713817; PubMed=21868764; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 9
ST   D18S51: 13,16
ST   D21S11: 30,31.2
ST   D3S1358: 16,17
ST   D5S818: 8,10
ST   D7S820: 11
ST   D8S1179: 11,17
ST   FGA: 20,21
ST   Penta D: 9,13
ST   Penta E: 18
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 14,18
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 32
RX   PubMed=2334411; DOI=10.1016/0006-291X(90)92335-W;
RA   Ishizaka Y., Ushijima T., Sugimura T., Nagao M.;
RT   "cDNA cloning and characterization of ret activated in a human
RT   papillary thyroid carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 168:402-408(1990).
RX   PubMed=2516841; DOI=10.1111/j.1349-7006.1989.tb01645.x;
RA   Ishizaka Y., Itoh F., Tahira T., Ikeda I., Ogura T., Sugimura T.,
RA   Nagao M.;
RT   "Presence of aberrant transcripts of ret proto-oncogene in a human
RT   papillary thyroid carcinoma cell line.";
RL   Jpn. J. Cancer Res. 80:1149-1152(1989).
RX   PubMed=2823470; DOI=10.1016/0042-6822(87)90171-1;
RA   Tanaka J., Ogura T., Sato H., Hatano M.;
RT   "Establishment and biological characterization of an in vitro human
RT   cytomegalovirus latency model.";
RL   Virology 161:62-72(1987).
RX   PubMed=7491517; DOI=10.1016/S0039-6060(05)80108-4;
RA   Jossart G.H., Greulich-Bode K.M., Siperstein A.E., Duh Q.-Y., Clark O.H.,
RA   Weier H.-U.G.;
RT   "Molecular and cytogenetic characterization of a t(1;10;21)
RT   translocation in the human papillary thyroid cancer cell line TPC-1
RT   expressing the ret/H4 chimeric transcript.";
RL   Surgery 118:1018-1023(1995).
RX   PubMed=11439348; DOI=10.1038/sj.onc.1204531;
RA   Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.;
RT   "Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile
RT   response to hepatocyte growth factor.";
RL   Oncogene 20:3845-3856(2001).
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
RX   PubMed=15980887; DOI=10.1038/labinvest.3700306;
RA   Nakamura N., Carney J.A., Jin L., Kajita S., Pallares J., Zhang H.-Y.,
RA   Qian X., Sebo T.J., Erickson L.A., Lloyd R.V.;
RT   "RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid
RT   tumors.";
RL   Lab. Invest. 85:1065-1075(2005).
RX   PubMed=16778181; DOI=10.1158/0008-5472.CAN-06-0171;
RA   Bonora E., Porcelli A.M., Gasparre G., Biondi A., Ghelli A.,
RA   Carelli V., Baracca A., Tallini G., Martinuzzi A., Lenaz G.,
RA   Rugolo M., Romeo G.;
RT   "Defective oxidative phosphorylation in thyroid oncocytic carcinoma is
RT   associated with pathogenic mitochondrial DNA mutations affecting
RT   complexes I and III.";
RL   Cancer Res. 66:6087-6096(2006).
RX   PubMed=17725429; DOI=10.1089/thy.2007.0097;
RA   Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V.,
RA   Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R.,
RA   Trovisco V., Cirnes L., Alves C., Velho S., Soares P.,
RA   Sobrinho-Simoes M.;
RT   "Molecular and genotypic characterization of human thyroid follicular
RT   cell carcinoma-derived cell lines.";
RL   Thyroid 17:707-715(2007).
RX   PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026;
RA   van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G.,
RA   Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.;
RT   "Human thyroid tumor cell lines derived from different tumor types
RT   present a common dedifferentiated phenotype.";
RL   Cancer Res. 67:8113-8120(2007).
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
RX   PubMed=19087340; DOI=10.1186/1471-2407-8-371;
RA   Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.;
RT   "Conventional and molecular cytogenetics of human non-medullary
RT   thyroid carcinoma: characterization of eight cell line models and
RT   review of the literature on clinical samples.";
RL   BMC Cancer 8:371.1-371.11(2008).
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
RX   PubMed=22087789; DOI=10.1186/1755-8166-4-26;
RA   Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.;
RT   "Centrosomal and mitotic abnormalities in cell lines derived from
RT   papillary thyroid cancer harboring specific gene alterations.";
RL   Mol. Cytogenet. 4:26.1-26.8(2011).
RX   PubMed=23162534; DOI=10.3389/fendo.2012.00133;
RA   Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A.,
RA   van Staveren W.C.G., Maenhaut C.;
RT   "Thyroid cancer cell lines: an overview.";
RL   Front. Endocrinol. 3:133.1-133.9(2012).
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).